Healthcare Industry News: HSMN NewsFeed
News Release - March 13, 2012
AstraZeneca Files Lawsuit against the FDA for Decision Regarding Quetiapine Product Labeling and ExclusivityWILMINGTON, Del.,--(Healthcare Sales & Marketing Network)--AstraZeneca (NYSE: AZN ) today announced that it has filed a lawsuit against the US Food and Drug Administration (FDA) in the US District Court for the District of Columbia to overturn the FDA’s denial on March 7, 2012 of the company’s Citizen Petitions with regard to SEROQUEL® (quetiapine fumarate) tablets and SEROQUEL XR® (quetiapine fumarate) extended release tablets.
In the Citizen Petitions, AstraZeneca raised important issues regarding labeling requirements for generic copies of innovative medicines, as well as data exclusivity rights granted to innovative companies that conduct new clinical trials.
AstraZeneca seeks an injunction barring the FDA from granting final marketing approval of generic quetiapine until December 2, 2012 when regulatory exclusivity expires on important clinical trial data, or, alternatively, at least until a federal court has a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications.
AstraZeneca will vigorously defend its legal rights.
About the Citizen Petitions
On September 9, 2011 AstraZeneca filed a Citizen Petition with the FDA for each of SEROQUEL and SEROQUEL XR, requesting the FDA withhold finally approving any generic quetiapine product that omits from its labeling certain warning language that FDA required AstraZeneca to include in the labeling for SEROQUEL and SEROQUEL XR. Data associated with the warning language at issue is protected by marketing exclusivity periods expiring as late as December 2, 2012.
The FDA denied both Citizen Petitions on March 7, 2012. The patent covering the active ingredient in SEROQUEL and SEROQUEL XR expired in September 2011, with pediatric exclusivity expiring on March 26, 2012. SEROQUEL XR is covered by a formulation patent that expires in May 2017, with pediatric exclusivity expiring in November 2017. In 2011, AstraZeneca granted both Handa and Accord a license to enter the US market with generic SEROQUEL XR on November 1, 2016, or earlier under certain circumstances.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsInsmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer